Safety Window Study on Correlation Between Docetaxel Steady-State AUC and Myelosuppression in Breast Cancer Patients
Identified the optimal docetaxel therapeutic window (AUC 1-1.6 mg·h·L⁻¹) in 101 breast cancer patients, demonstrating reduced myelosuppression risk and potential to avoid …
yunyun-xu